Fatigue and depression are very common, highly significant symptoms of MS and are a major cause of reduced quality of life in MS. Fatigue affects up to 80% of people with MS and often presents early in the disease course.
A large long-running Australian study, known as the AusLong study, which has followed over 400 Australians for over 15 years, has shown that 5 years after a first clinical demyelinating event, 41% of people with early MS experienced fatigue, and 19% experienced clinical depression. Despite its huge impact, one of the unfulfilled needs in MS is an effective treatment option to combat fatigue.
Treatments that improve function of mitochondria (the parts of a cell which produce energy) might slow the neurological damage and have a protective effect, whilst also reducing fatigue. While some single drugs and agents that support mitochondrial function have shown promise in reducing fatigue, depression and brain shrinkage, a combined therapy of multiple mitochondrial support agents has not previously been tested in MS.
As part of a larger clinical trial that has been funded by the Federal Government’s Medical Research Future Fund, this project will test whether MRI techniques can be used to assess the efficacy of a combined dietary supplement that targets mitochondrial function and can help combat fatigue and depression in a relapsing remitting multiple sclerosis (RRMS).
Updated: 23 January 2018
Updated: 02 January, 2019
Laboratory research that investigates scientific theories behind the possible causes, disease progression, ways to diagnose and better treat MS.
Research that builds on fundamental scientific research to develop new therapies, medical procedures or diagnostics and advances it closer to the clinic.
Clinical research is the culmination of fundamental and translational research turning those research discoveries into treatments and interventions for people with MS.